Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 30, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on October 26, 2006:
- Previous Holdings: 17,391,816 Ordinary Share ADRs
- New Holdings: 17,355,409 Ordinary Share ADRs
- Average Price: $56.20
Two directors, Dr. J-P Garnier and Dr. M M Slaoui, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of the share transaction under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the impact of the reduction in ADR holdings (36,407 shares) on the total beneficial ownership of the Plan.
- Confirm the specific nature of the "fund movement" that triggered the change in share count.
- Review the broader context of Director interests in the Plan to ensure compliance with internal governance policies.